Experimental HCV Drugs
Experimental HCV Drugs
Daclatasvir, Asunaprevir, and Beclabuvir Shows High Cure Rates for People with Genotype 1 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 13 May 2015 00:00
- Written by Liz Highleyman
A twice-daily fixed-dose coformulation of daclatasvir, asunaprevir, and beclabuvir taken for 12 weeks cured 91% of genotype 1 chronic hepatitis C patients without liver cirrhosis, and even higher sustained response rates were obtained for people with cirrhosis when ribavirin was added, according to findings from the Phase 3 UNITY studies published in the May 5 issue of JAMA.
EASL 2015: Sofosbuvir/ Ledipasvir Cures More Than 90% of People with Hepatitis C Genotypes 4 and 5
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 May 2015 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
EASL 2015: Grazoprevir/ Elbasvir Effective for Treatment-Experienced and HIV/HCV Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 27 April 2015 00:00
- Written by Keith Alcorn
The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C virus infection in 12 weeks in some groups of treatment-experienced patients and in HIV/HCV coinfected people, and a 16-week course of treatment with ribavirin was highly effective even for the hardest-to-treat groups of treatment-experienced patients, according to 2 studies presented last week at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.
EASL 2015: Grazoprevir/ Elbasvir Is Highly Effective for Previously Untreated Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 27 April 2015 00:00
- Written by Keith Alcorn
A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with hepatitis C virus gentoypes 1, 4, or 6, according to results of the C-EDGE trial presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. However, the study also showed that people with higher baseline HCV viral load and genotype 1a may have a poorer response to this combination, particularly if they have naturally occurring HCV variants that are less sensitive to drugs from the NS5A inhibitor class.
EASL 2015: Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 23 April 2015 00:00
- Written by Keith Alcorn
A 12-week course of treatment with 2 direct-acting antivirals in development by Merck cured hepatitis C virus infection in 90% of people with very advanced cirrhosis and at imminent risk of liver failure, Ira Jacobson of Weill Cornell Medical College reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna. The Phase 2 study looked at the use of the HCV protease inhibitor grazoprevir and the NS5A inhibitor elbasvir in people with Child-Pugh B cirrhosis.
More Articles...
- EASL 2015: Merck HCV Combination Effective after Failure of First Generation Direct-Acting Antivirals
- Allergy Drug Inhibits Hepatitis C Virus Replication in Mouse Study
- Janssen Interferon-Free Regimen with Simeprevir Cures Most Patients with Genotype 1 HCV
- FDA Will Consider Approval of Daclatasvir for Genotype 3 Hepatitis C Treatment
Web Design and Development by